Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA mutations in advanced cancers: characteristics and outcomes.

Oncotarget - 1 Dec 2012

Janku Filip, Wheler Jennifer J, Naing Aung, Stepanek Vanda M, Falchook Gerald S, Fu Siqing, Garrido-Laguna Ignacio, Tsimberidou Apostolia M, Piha-Paul Sarina A, Moulder Stacy L, Lee Jack J, Luthra Rajyalakshmi, Hong David S, Kurzrock Razelle

Abstract excerpt

PIK3CA mutations are frequently diagnosed in diverse cancers and may predict response to PI3K/AKT/mTOR inhibitors. It remains unclear whether they are associated with other characteristics. We analyzed characteristics and outcome of 90 consecutive patients with diverse advanced tumors and PIK3CA mutations and 180 wild-type PIK3CA controls matched by tumor type, gender, and age referred to the Clinical Center for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to GTP Phosphohydrolases

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins c-akt

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 23248156
DOI: 10.18632/oncotarget.716
PMCID: PMC3681495

Genes

KRAS
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA mutations in advanced cancers: characteristics and outcomes.PMID 23248156Read ↗

PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.Semantic proximity Read ↗

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.Semantic proximity Read ↗

Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.Semantic proximity Read ↗

Prognostic and Predictive Value of PIK3CA Mutations in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Semantic proximity Read ↗

PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.Semantic proximity Read ↗

PIK3CA gene aberrancy and role in targeted therapy of solid malignancies.Semantic proximity Read ↗

The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer.Semantic proximity Read ↗

Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer.Semantic proximity Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.Semantic proximity Read ↗

Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.